Use of probiotics in HIV-positive individuals
DOI:
https://doi.org/10.34019/1982-8047.2020.v46.28233Keywords:
HIV, Acquired Immune Deficiency Syndrome, ProbioticAbstract
Introduction: The human immunodeficiency virus (HIV), which progressively reduces the effectiveness of the immune system, increases the susceptibility to opportunistic infections. In addition, it increases intestinal permeability and microbial translocation, which contribute to systemic immune activation, characterizing the evolution to Acquired Immunodeficiency Syndrome (AIDS). Immunological modulation of the gastrointestinal barrier in HIV with the use of probiotics has beneficial effects on host microbial balance. Objective: The present study aimed to gather data from the clinical studies literature regarding the use of probiotics in HIV-infected patients using or not antiretroviral therapy. Material and Methods: A review of the scientific literature was performed through PUBMED using the following descriptors in Health Sciences (DeCS), either alone or in combination: “human immunodeficiency virus”, “HIV”, “probiotics”. We selected studies from randomized controlled trials that involved addressing the use of probiotics in HIV-infected patients. Eleven articles with content that contributed to the fulfillment of the objectives of this study were selected. The articles were included in the English language, published in 2014 and 2018. Results: In addition to the different characteristics of the patients selected in the studies, different probiotics were tested. Interactions with immune receptors and intestinal microbiota have not yet been fully defined and may have different effects on intestinal regulation and systemic immunity. Conclusions: Understanding the interaction between the intestinal microbiome and its products in adjusting immunity in the HIV + individual will allow us to define new interventions that may decrease inflammation and disease-associated comorbidities.
Downloads
References
Zevin AS, Mckinnon L, Burgener A, Klatt NR. Microbial translocation and microbiome dysbiosis in HIV-associated immune activation. Curr Opin HIV AIDS. 2017; 11:182-90.
Thaiss CA, Levy M, Suez J, Elinav E. The interplay between the innate immune system and the microbiota. Curr Opin Immunol. 2014; 26:41-8.
Villar-García J, Hernández JJ, Güerri-Fernández R, González A, Lerma E, Guelar A, Saenz D, Sorlí L, Montero M, Horcajada JP, Knobel Freud H. Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: a double-blind, randomized, placebo-controlled trial. J Acquir Immune Defic Syndr. 2015; 68:256-63.
Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev. 2013; 254:326-42.
Joint United Nations Programme on HIV/AIDS. Resumo informativo: estatísticas globais sobre HIV [internet]. Brasília: 2017. [Acesso em 2018 May 11]. Disponível em: https://unaids.org.br/wp-content/uploads/2017/12/UNAIDSBR_FactSheet.pdf.
Ministério da Saúde (BR). Boletim epidemiológico HIV/AIDS. Brasília: 2017.
Pope M, Haase AT. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med. 2003; 9:847-52.
Geskus RB, Prins M, Hubert JB, Miedema F, Berkhout B, Rouzioux C et al. The HIV RNA setpoint theory revisited. Retrovirology. 2007; 4:1-9.
Simon V, Ho DD, Karim QA. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet. 2006; 368:489-504.
Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Douek DC. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12:1365-71.
Dinh DM, Volpw GE, Duffalo C, Bhalchandra S, Tai AK, Kane AV et al. Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection. J Infect Dis. 2015; 211:19-27.
Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett. 2009; 294:1-8.
Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol. 2012; 10:655-66.
Estes JD, Harris LD, Klatt NR, Tabb B, Pittaluga S, Paiardini et al. Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog. 2010; 6:1-12.
Nazli A, Chan O, Dobson-Belaire WN, Ouellet M, Tremblay MJ, Gray-Owen et al. Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog. 2010; 6:1-20.
Yim HC, Li JC, Lau JS, Lau AS. HIV-1 Tat dysregulation of lipopolysaccharide-induced cytokine responses: Microbial interactions in HIV infection. AIDS. 2009; 23:1473-84.
Brenchley JM, Douek DC. Microbial translocation across the GI tract. Annu Rev Immunol. 2012; 30:149-73.
Erlandson KM, Allshouse AA, Jankowski CM, Lee EJ, Rufner KM, Palmer BE et al. Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. Journal of Infectious Diseases. 2013; 208:249-59.
Koethe JR, Dee K, Bian A, Shintani A, Turner M, Bebawy S et al. Circulating interleukin-6, soluble CD14, and other inflammation biomarker levels differ between obese and nonobese HIV-infected adults on antiretroviral therapy. AIDS Res Hum Retroviruses. 2013; 29:1019-25.
Stehle JR, Leng X, Kitzman DW, Nicklas BJ, Kritchevsky SB, High KP. Lipopolysaccharide-binding protein, a surrogate marker of microbial translocation, is associated with physical function in healthy older adults. J Gerontol A Biol Sci Med Sci. 2012; 67:1212-8.
Stein DS, Lyles RH, Graham NM, Tassoni CJ, Margolick JB, Phair JP et al. Predicting clinical progression or death in subjects with early-stage human immunodeficiency virus (HIV) infection: a comparative analysis of quantification of HIV RNA, soluble tumor necrosis factor type II receptors, neopterin, and beta2-microglobulin. Multicenter AIDS Cohort Study. J Infect Dis. 1997; 176:1161-7.
Nixon DE, Landay AL. Biomarkers of immune dysfunction in HIV. Curr Opin HIV/AIDS. 2010; 5:498-503.
Mchardy IH, Li X, Tong M, Ruegger P, Jacobs J, Borneman J et al. HIV infection is associated with compositional and functional shifts in the rectal mucosal microbiota. Microbiome. 2013; 1:1-12.
Lozupone CA, Rhodes ME, Neff CP, Fontenot AP, Campbell TB, Palmer BE. HIV-induced alteration in gut microbiota: driving factors, consequences, and effects of antiretroviral therapy. Gut Microbes. 2014; 5:562-70.
Leblanc JG, Milani C, Giori GS, Sesma F, Van Sinderen D, Ventura M. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol. 2013; 24:160-68.
Ceccarelli G, Fratino M, Selvaggi C. A pilot study on the effects of probiotic supplementation on neuropsychological performance and micro-RNA-29a-c levels in antiretroviral-treated HIV-1-infected patients. Brain Behavior. 2016; 7:e00756.
Ceccarelli G, Fratino M, Selvaggi C, Giustini N, Serafino S, Schietroma I et al. A pilot study on the effects of probiotic supplementation on neuropsychological performance and microRNA-29a-c levels in antiretroviral-treated HIV-1-infected patients. Brain Behavior. 2017; 7:e00756.
Arnbjerg CJ, Vestad B, Hov JR, Pedersen KK, Jespers S, Johannesen HH et al. Effect of Lactobacillus rhamnosus GG supplementation on intestinal inflamation assessed by PET/MRI scans and gut microbiota composition in HIV infected individuals. J Acquir Immune Defic Syndr. 2018; 78:450-7.
D’ettorre G, Rossi G, Scagnolari C. Probiotic supplementation promotes a reduction in T-cell activation, an increase in Th17 frequencies and a recovery of intestinal epithelium integrity and mitochondrial morphology in ART-treated HIV-1-positive patients. Immun Inflamm Dis. 2017; 5:244-60.
D’ettorre G, Ceccarelli G, Giustini N. Probiotics reduce inflammation in antiretroviral treated, HIV-infected individuals: results of the ‘Probio-HIV’ clinical trial. PLoS One. 2015; 10:e01372005.
Ishizaki A, Bi X, Nguyen LV, Matsud K, Pham HV, Phan CTT et al. Effects of short-term probiotic ingestion on immune profiles and microbial translocation among HIV-1-infected vietnamese children. Int J Mol Sci. 2017; 18:2185.
Stiksrud B, Nowak P, Nwosu FC, Kvale D, Thalme A, Sonnerborg A et al. Reduced levels of D-dimer and changes in gut microbiota composition after probiotic intervention in HIV-infected individuals on stable ART. J Acquir Immune Defic Syndr. 2015; 70:329-37.
Falasca K, Vecchiet J, Ucciferri C. Effect of probiotic supplement on cytokine levels in HIV-infected individuals: a preliminary study. Nutrients. 2017; 7:8335-47.
Bron PA, Van Baarlen P, Kleerebezem M. Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nat Rev Microbiol. 2011; 10:66-78.
Yang OO, Kelesidis T, Cordova R, Khanlou H. Immunomodulation of antiretroviral drug-suppressed. AIDS Res Hum Retroviruses. 2014; 30:988-95.
Serrano-Villar S, Lagarde M, Vázquez-Castellanos J, Bernadino JI, Madrid N, Matarranz M et al. Effects of immunonutrition in advanced HIV disease: a randomized placebo controlled clinical trial (Promaltia Study). Clin Infect Dis. 2019; 68(1):120-30.
Downloads
Published
How to Cite
Issue
Section
License
Cessão de Primeira Publicação à HU Revista
Os autores mantém todos os direitos autorais sobre a publicação, sem restrições, e concedem à HU Revista o direito de primeira publicação, com o trabalho licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento irrestrito do trabalho, com reconhecimento da autoria e crédito pela citação de publicação inicial nesta revista, referenciando inclusive seu DOI.
